Capping Medicare beneficiaries’ monthly insulin out-of-pocket costs at $35 was associated with steep reductions in spending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results